Dried fluid spots for HIV type-1 viral load and resistance genotyping: A systematic review

Antiviral Therapy

Volumn 14, Issue 5, 2009, Pages 619-629

  Hamers, Raph L ^a   Smit, Pieter W ^a,b   Stevens, Wendy ^c,d   Schuurman, Rob ^e   Rinke de Wit, Tobias F ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^d NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

BLOOD SAMPLING; BLOOD SMEAR; CLINICAL TRIAL; DRIED FLUID SPOT; FEASIBILITY STUDY; FILTER; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LABORATORY TEST; PRIORITY JOURNAL; REVIEW; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; VIRUS LOAD; VIRUS RESISTANCE;

ANTI-HIV AGENTS; BLOOD SPECIMEN COLLECTION; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; PLASMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; VIRAL LOAD;

EID: 69849095336     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Palella FJ, Jr., Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-860.
2. Hammer SM, Eron JJ, Jr., Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society - USA panel. JAMA 2008; 300:555-570.
3. Crowe S, Turnbull S, Oelrichs R, Dunne A. Monitoring of human immunodeficiency virus infection in resource-constrained countries. Clin Infect Dis 2003; 37 Suppl 1:S25-S35.
4. UNAIDS, WHO. 2008 Report on the global AIDS epidemic. (Accessed 10 December 2008.) Available from http://www.unaids.org/en/KnowledgeCentre/ HIVData/GlobalReport/2008/2008_Global_report.asp
5. McCabe ER, Huang SZ, Seltzer WK, Law ML. DNA microextraction from dried blood spots on filter paper blotters: potential applications to newborn screening. Hum Genet 1987; 75:213-216.
6. Mei JV, Alexander JR, Adam BW, Hannon WH. Use of filter paper for the collection and analysis of human whole blood specimens. J Nutr 2001; 131:1631S-1636S.
7. Hoff R, Berardi VP, Weiblen BJ, Mahoney-Trout L, Mitchell ML, Grady GF. Seroprevalence of human immunodeficiency virus among childbearing women. Estimation by testing samples of blood from newborns. N Engl J Med 1988; 318:525-530.
8. Gwinn M, Pappaioanou M, George JR, et al. Prevalence of HIV infection in childbearing women in the United States. Surveillance using newborn blood samples. JAMA 1991; 265:1704-1708.
9. Evengard B, Ehrnst A, von Sydow M, Pehrson PO, Lundbergh P, Linder E. Effect of heat on extracted HIV viral infectivity and antibody activity using the filter paper technique of blood sampling. AIDS 1989; 3:591-595.
10. Comeau AM, Pitt J, Hillyer GV, et al. Early detection of human immunodeficiency virus on dried blood spot specimens: sensitivity across serial specimens. Women and Infants Transmission Study Group. J Pediatr 1996; 129:111-118.
11. Sherman GG, Stevens G, Jones SA, Horsfield P, Stevens WS. Dried blood spots improve access to HIV diagnosis and care for infants in low-resource settings. J Acquir Immune Defic Syndr 2005; 38:615-617.
12. Stevens W, Erasmus L, Moloi M, Taleng T, Sarang S. Performance of a novel human immunodeficiency virus (HIV) type 1 total nucleic acid-based real-time PCR assay using whole blood and dried blood spots for diagnosis or HIV in infants. J Clin Microbiol 2008; 46:3941-3945.
13. Alvarez-Munoz MT, Zaragoza-Rodriguez S, Rojas-Montes O, et al. High correlation of human immunodeficiency virus type-1 viral load measured in dried-blood spot samples and in plasma under different storage conditions. Arch Med Res 2005; 36:382-386.
14. Ayele W, Schuurman R, Messele T, et al. Use of dried spots of whole blood, plasma, and mother's milk collected on filter paper for measurement of human immunodeficiency virus type 1 burden. J Clin Microbiol 2007; 45:891-896.
15. Brambilla D, Jennings C, Aldrovandi G, et al. Multicenter evaluation of use of dried blood and plasma spot specimens in quantitative assays for human immunodeficiency virus RNA: measurement, precision, and RNA stability. J Clin Microbiol 2003; 41:1888-1893.
16. Fiscus SA, Brambilla D, Grosso L, Schock J, Cronin M. Quantitation of human immunodeficiency virus type 1 RNA in plasma by using blood dried on filter paper. J Clin Microbiol 1998; 36:258-260.
17. Kane CT, Ndiaye HD, Diallo S, et al. Quantitation of HIV-1 RNA in dried blood spots by the real-time NucliSENS EasyQ HIV-1 assay in Senegal. J Virol Methods 2008; 148:291-295.
18. Mwaba P, Cassol S, Nunn A, et al. Whole blood versus plasma spots for measurement of HIV-1 viral load in HIV-infected African patients. Lancet 2003; 362:2067-2068.
19. O'Shea S, Mullen J, Corbett K, Chrystie I, Newell ML, Banatvala JE. Use of dried whole blood spots for quantification of HIV-1 RNA. AIDS 1999; 13:630-631.
20. Uttayamakul S, Likanonsakul S, Sunthornkachit R, et al. Usage of dried blood spots for molecular diagnosis and monitoring HIV-1 infection. J Virol Methods 2005; 128:128-134.
21. Waters L, Kambugu A, Tibenderana H et al. Evaluation of filter paper transfer of whole-blood and plasma samples for quantifying HIV RNA in subjects on antiretroviral therapy in Uganda. J Acquir Immune Defic Syndr 2007; 46: 590-593.
22. Amellal B, Katlama C, Calvez V. Evaluation of the use of dried s ots and of different storage conditions of plasma for HIV-1 RNA quantification. HIV Med 2007; 8:396-400.
23. Cassol S, Gill MJ, Pilon R, et al. Quantification of human immunodeficiency virus type 1 RNA from dried plasma spots collected on filter paper. J Clin Microbiol 1997; 35:2795-2801.
24. Idigbe EO, Ekong EE, Salu OB, et al. Primagen retina TM rainbow viral load assay: a feasible for assay for resource limited settings- the Nigerian experience. 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. 3-16 July 2003, Paris, France. Abstract LB38.
25. Abravaya K, SH, Erickson B, Mak WB. The use of dried blood spots with the Abbott RealTime HIV-1 viral load assay. XVII International AIDS Conference. 3-8 August 2008, Mexico City, Mexico. Abstract CDB0034.
26. Abdo M, Sherman G, Stevens W. Validation of the NucliSens EasyQ assay on dried fluid spots for monitoring of HIV-1 infection in South Africa. 15th Conference on Retroviruses and Opportunistic Infections. 3-6 February 2008, Boston, MA, USA: Abstract 925.
27. Bertagnolio S, Soto-Ramirez L, Pilon R, et al. HIV-1 drug resistance surveillance using dried whole blood spots. Antivir Ther 2007; 12:107-113.
28. Buckton AJ, Bissett SL, Myers RE, et al. Development and optimization of an internally controlled dried blood spot assay for surveillance of human immunodeficiency virus type-1 drug resistance. J Antimicrob Chemother 2008; 62:1191-1198.
29. Dachraoui R, Brand D, Brunet S, Barin F, Plantier JC. RNA amplification of the HIV-1 pol and env regions on dried serum and plasma spots. HIV Med 2008; 9:557-561.
30. Dachraoui R, Depatureaux A, Chakroun M, et al. Monitoring of HIV-1 resistance in Tunisia (North Africa) with a dried plasma spot strategy. J Acquir Immune Defic Syndr 2008; 47:522-525.
31. Garrido C, Zahonero N, Fernandes D, et al. Subtype variability virological response and drug resistance assessed on dried blood spots collected from HIV patients on antiretroviral therapy in Angola. J Antimicrob Chemother 2008; 61:694-698.
32. Hallack R, Doherty LE, Wethers JA, Parker MM. Evaluation of dried blood spot specimens for HIV-1 drug-resistance testing using the Trugene HIV-1 genotyping assay. J Clin Virol 2008; 41:283-287.
33. Masciotra S, Garrido C, Youngpairoj AS, et al. High concordance between HIV-1 drug resistance genotypes generated from plasma and dried blood spots in antiretroviral-experienced patients. AIDS 2007; 21:2503-2511.
34. McNulty A, Jennings C, Bennett D, et al. Evaluation of dried blood spots for human immunodeficiency virus type 1 drug resistance testing. J Clin Microbiol 2007; 45:517-521.
35. Plantier JC, Dachraoui R, Lemee V, et al. HIV-1 resistance genotyping on dried serum spots. AIDS 2005; 19:391-397.
36. Steegen K, Luchters S, Demecheleer E, et al. Feasibility of detecting human immunodeficiency virus type 1 drug resistance in DNA extracted from whole blood or dried blood spots. J Clin Microbiol 2007; 45:3342-3351.
37. Youngpairoj AS, Masciotra S, Garrido C, Zahonero N, de Mendoza C, Garcia-Lerma JG. HIV-1 drug resistance genotyping from dried blood spots stored for 1 year at 4 degrees C. J Antimicrob Chemother 2008; 61:1217-1220.
38. Ziemniak C, George-Agwu A, Moss WJ, Ray SC, Persaud D. A sensitive genotyping assay for detection of drug resistance mutations in reverse transcriptase of HIV-1 subtypes B and C in samples stored as dried blood spots or frozen RNA extracts. J Virol Methods 2006; 136:238-247.
39. Knuchel MC, Tomasik Z, Speck RF, Luthy R, Schupbach J. Ultrasensitive quantitative HIV-1 p24 antigen assay adapted to dried plasma spots to improve treatment monitoring in low-resource settings. J Clin Virol 2006; 36:64-67.
40. Stevens G, Rekhviashvili N, Scott LE, Gonin R, Stevens W. Evaluation of two commercially available, inexpensive alternative assays used for assessing viral load in a cohort of human immunodeficiency virus type 1 subtype C-infected patients from South Africa. J Clin Microbiol 2005; 43:857-861.
41. + lymphocyte counts in HIV-1-infected patients. Lancet 2003; 362:1459-1460.
42. World Health Organization. HIV drug resistance. (Accessed 10 December 2008.) Available from http://www.who.int/hiv/topics/drugresistance
43. Noe A, Plum J, Verhofstede C. The latent HIV-1 reservoir in patients undergoing HAART: an archive of pre-HAART drug resistance. J Antimicrob Chemother 2005; 55:410-412.
44. Verhofstede C, Noe A, Demecheleer E, et al. Drug-resistant variants that evolve during nonsuppressive therapy persist in HIV-1-infected peripheral blood mononuclear cells after long-term highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2004; 35:473-483.
45. Bi X, Gatanaga H, Ida S, et al. Emergence of protease inhibitor resistance-associated mutations in plasma HIV-1 precedes that in proviruses of peripheral blood mononuclear cells by more than a year. J Acquir Immune Defic Syndr 2003; 34:1-6.
46. Bruisten SM, Reiss P, Loeliger AE, et al. Cellular proviral HIV type 1 DNA load persists after long-term RT-inhibitor therapy in HIV type 1 infected persons. AIDS Res Hum Retroviruses 1998; 14:1053-1058.
47. Chun TW, Carruth L, Finzi D, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997; 387:183-188.
48. Escaich S, Ritter J, Roger P, et al. Relevance of the quantitative detection of HIV proviral sequences in PBMC. of infected individuals. AIDS Res Hum Retroviruses 1992; 8:1833-1837.
49. Driver GA, Patton JC, Moloi J, Stevens WS, Sherman GG. Low risk of contamination with automated and manual excision of dried blood spots for HIV DNA PCR testing in the routine laboratory. J Virol Methods 2007; 146:397-400.
50. Akane A, Matsubara K, Nakamura H, Takahashi S, Kimura K. Identification of the heme compound copurified with deoxyribonucleic acid (DNA) from bloodstains, a major inhibitor of polymerase chain reaction (PCR) amplification. J Forensic Sci 1994; 39:362-372.
51. Boom R, Sol CJ, Salimans NM, et al. Rapid and simple method for purification of nucleic acids. J Clin Microbiol 1990; 28:495-503.